These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3158674)

  • 21. A comparative study of ketanserin and metoprolol in essential hypertension.
    Kane JA; Tooley M; Sibbald B; Gould SE
    J Hypertens Suppl; 1986 Apr; 4(1):S63-5. PubMed ID: 2939215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlled trial of ketanserin in hypertension.
    McGourty JC; Silas JH; Cowen KJ
    Br J Clin Pharmacol; 1985 Jul; 20(1):37-40. PubMed ID: 3161531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of ketanserin, a 5-hydroxytryptamine receptor antagonist, for treatment of postoperative hypertension following coronary artery bypass surgery.
    van der Starre PJ; Scheijgrond HW; Reneman RS; Kolling JB
    Anesth Analg; 1983 Jan; 62(1):63-9. PubMed ID: 6600382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic and hemodynamic effects of antihypertensive treatment with ketanserin.
    Levinson PD; Zimlichman R; Goldstein DS; Brewer HB; Keiser HR
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):245S-248S. PubMed ID: 3415801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
    Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood pressure, 5-OH indoleacetic acid, and vanilmandelic acid excretion and blood platelet aggregation in hypertensive patients treated with ketanserin.
    Dzúrik R; Fetkovská N; Brimichová G; Tison P
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S29-31. PubMed ID: 2412052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication.
    De Cree J; Leempoels J; Geukens H; Verhaegen H
    Lancet; 1984 Oct; 2(8406):775-9. PubMed ID: 6148522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative and long-term evaluation of ketanserin in the treatment of essential hypertension.
    Hedner T; Persson B; Berglund G
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S148-53. PubMed ID: 2412038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency.
    Wenting GJ; Woittiez AJ; Man in't Veld AJ; Schalekamp MA
    Hypertension; 1984; 6(1):100-9. PubMed ID: 6319278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of arterial hypertension with ketanserin in mono- and combination therapy.
    Pettersson A; Persson B; Berglund G; Hedner T
    Clin Pharmacol Ther; 1985 Aug; 38(2):188-94. PubMed ID: 2861930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Control of preeclamptic hypertension by ketanserin, a new serotonin receptor antagonist.
    Weiner CP; Socol ML; Vaisrub N
    Am J Obstet Gynecol; 1984 Jul; 149(5):496-500. PubMed ID: 6377898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ketanserin in the acute management of severe hypertension.
    Murphy BF; Whitworth JA; Kincaid-Smith P
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S168-71. PubMed ID: 2412044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension.
    Fagard R; Fiocchi R; Lijnen P; Staessen J; Moerman E; de Schaepdryver A; Amery A
    Br Heart J; 1984 Feb; 51(2):149-56. PubMed ID: 6362688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute hemodynamic effects of pinacidil and hydralazine in essential hypertension.
    Carlsen JE; Kardel T; Lund JO; McNair A; Trap-Jensen J
    Clin Pharmacol Ther; 1985 Mar; 37(3):253-9. PubMed ID: 2857601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
    J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ketanserin in the treatment of essential hypertension. A double-blind study against metoprolol and a further long-term open treatment.
    Milei J; Lemus J; Bernardiner E
    Acta Cardiol; 1986; 41(6):427-41. PubMed ID: 3544622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of angiotensin antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients.
    Rhéaume C; Waib PH; Lacourcière Y; Cléroux J
    J Hypertens; 1998 Dec; 16(12 Pt 2):2085-9. PubMed ID: 9886901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of ketanserin in essential hypertension.
    Anderson A; Morgan T; Dumpys R
    Clin Exp Pharmacol Physiol; 1983; 10(3):331-3. PubMed ID: 6627748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and haemodynamic effects of ketanserin in lean and obese hypertensive patients.
    Licata G; Scaglione R; Parrinello G; Capuana G; Mazzola G; Lipari R; Castello R; Galantino L
    J Int Med Res; 1990; 18(2):112-9. PubMed ID: 2340944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of treatment with ACE and serotonin inhibitors on arterial blood pressure at rest and cycloergometric exercise and on systolic time intervals: comparison of enalapril and ketanserin].
    Cumetti CM; Brina A
    Ann Ital Med Int; 1990; 5(4 Pt 2):503-23. PubMed ID: 2102138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.